Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of “Moderate Buy” by Brokerages

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $18.75.

A number of equities analysts recently commented on the company. HC Wainwright decreased their price target on Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Guggenheim reaffirmed a “buy” rating and set a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Benchmark reiterated a “speculative buy” rating and issued a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 20th. Zacks Research upgraded Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Wall Street Zen raised Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th.

Unicycive Therapeutics Price Performance

NASDAQ UNCY opened at $5.16 on Monday. The company has a market capitalization of $143.71 million, a price-to-earnings ratio of -2.95 and a beta of 1.79. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $8.74. The company’s fifty day moving average price is $5.34 and its two-hundred day moving average price is $6.52.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.41. As a group, analysts anticipate that Unicycive Therapeutics will post -1.17 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Seven Fleet Capital Management LP boosted its holdings in shares of Unicycive Therapeutics by 85.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after buying an additional 47,700 shares during the period. Bank of New York Mellon Corp bought a new position in Unicycive Therapeutics in the second quarter worth about $248,000. Bank of America Corp DE boosted its stake in Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after acquiring an additional 29,378 shares during the period. Renaissance Technologies LLC acquired a new position in Unicycive Therapeutics in the first quarter valued at approximately $161,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Unicycive Therapeutics during the first quarter valued at approximately $940,000. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.